Skip to contentA
Arcus Biosciences, Inc.
A
RCUSArcus Biosciences, Inc. Q3 2024 · 10-Q
Revenue$7.00M$7.00M−78.1% vs Q3 2023 Net Income-$92.00M-$92.00MN/M vs Q3 2023 EPS Diluted-$1.00-$1.00N/M vs Q3 2023 Operating Income-$105,000,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Arcus Biosciences, Inc. · CIK 1724521 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$25,000,000N/M Margins · derivedOperating margin-1500.0%−1250.0 pt vs Q3 2023
Net margin-1314.3%−1092.4 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 6, 2024 · 37 d after period end